Press Releases

– Topline 12-week results for Phase 2 study of UBX0101 in osteoarthritis expected in 3Q 2020 – – First-in-human study for UBX1325 in age-related eye disease expected to commence in 2H 2020 – SOUTH SAN FRANCISCO, Calif. , July 01, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc.

SAN FRANCISCO , June 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the

SOUTH SAN FRANCISCO, Calif. , May 07, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the first quarter ended March

SAN FRANCISCO , May 04, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the first quarter ended

– Topline 12- and 24-week results expected in 2H 2020 – SAN FRANCISCO , March 31, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced updates

SOUTH SAN FRANCISCO, Calif. , March 30, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. today announced that Anirvan Ghosh , Ph.D., has officially joined the company as Chief Executive Officer. As previously announced, Dr. Ghosh is a renowned scientist and drug development leader who joins UNITY

SOUTH SAN FRANCISCO, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the fourth quarter and full

SAN FRANCISCO , March 03, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the fourth quarter and

– Renowned Scientist and Drug Developer Joins UNITY’s Mission to Extend Healthspan  – – Succeeds Keith Leonard Who Will Continue as Chairman – SAN FRANCISCO , March 02, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology today announced the appointment of Anirvan Ghosh , Ph.D., as CEO and member of the

– Phase 2 study of UBX0101 in patients with osteoarthritis has completed enrollment – – Topline 12- and 24-week results now expected in 2H 2020 – – First patient dosed in phase 1b study to explore higher dose and repeat doses – – First-in-human study initiation for ophthalmology program expected in